Navigation Links
Powerful New Efficacy Data in Moderate and Severe Hypertensive Patients Supports FDA Approval of AVALIDE(R) (Irbesartan-Hydrochlorothiazide) as the First Combination Therapy for Initial Use in Patients Likely to Need Multiple Drugs to Achieve Their Blood
Date:11/19/2007

f the hydrochlorothiazide component, AVALIDE is

contraindicated in patients with anuria or hypersensitivity to

sulfonamide-derived drugs

-- In patients with volume or sodium depletion (eg, patients vigorously

treated with diuretics or on dialysis), such depletion should be

corrected prior to administration of AVAPRO(R) (irbesartan) or

AVALIDE(R) (irbesartan-hydrochlorothiazide), or a lower initial dose of

AVAPRO (75 mg) should be used, to avoid possible symptomatic

hypotension

-- Hypersensitivity reactions to hydrochlorothiazide may occur in patients

with or without a history of allergy or bronchial asthma, but are more

likely in patients with such a history

-- Thiazide diuretics have been reported to cause exacerbation or

activation of systemic lupus erythematosus

-- Lithium generally should not be given with thiazides

-- Thiazides should be used with caution in patients with severe renal

disease and in patients with impaired hepatic function or progressive

liver disease, since minor alterations of fluid and electrolyte balance

may precipitate hepatic coma

-- In placebo-controlled hypertension studies, there were no significant

differences in adverse events (AEs) between AVAPRO and

placebo. Adverse events that occurred in at least 1% of patients

treated with AVAPRO and at a higher incidence vs placebo included

diarrhea (3% vs 2%), dyspepsia/heartburn (2% vs 1%) and fatigue (4% vs

3%)

-- Additionally, in a study of hypertensive type 2 diabetic patients with

renal disease (proteinuria greater than or equal to 900 mg/day), the

reported AEs for AVAPRO were similar to those seen in hypertension

studies, with the exception of an increased incidence of orthostatic

symptoms; AVAPRO compared to placebo (both groups received adjunc
'/>"/>

SOURCE Bristol-Myers Squibb Company
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Cytokine Demonstrates Oral Efficacy of Small-Molecule MIF Inhibitors
2. New Study Supports Efficacy of Vagus Nerve Stimulation for Treatment-Resistant Depression
3. New Study Presented at WorldSleep 2007 Demonstrates Ramelteon Has Sustained Efficacy Over Six Months in Adults With Chronic Insomnia
4. Five-Year Data From Taxus II Clinical Trial Highlights Safety and Efficacy of Taxus(R) Stent Compared to Bare-Metal Stent
5. Lpath Demonstrates Preclinical Efficacy of Lpathomab(TM) and Initiates Humanization Process
6. Ortho Biotech Reiterates Confidence in PROCRIT(R) (Epoetin alfa) Safety and Efficacy When Used According to Label
7. Phase III Clinical Trial in Newly Diagnosed Multiple Myeloma Stopped Early Due to Highly Significant Efficacy Advantage of VELCADE(R) (Bortezomib) for Injection Based Therapy Across All Endpoints
8. New Phase 3 Study in Treatment-Naive Adults with HIV Evaluates Efficacy and Safety of Once-Daily PREZISTA(TM)/ritonavir vs. KALETRA(R) as Part of HIV Combination Therapy
9. Targanta Presents First Data Demonstrating In Vitro Activity and In Vivo Efficacy of Prodrugs in Osteomyelitis Models
10. Further Data on Safety and Efficacy of Cethromycin Presented at 47th Interscience Conference on Antimicrobial Agents and Chemotherapy
11. Further Data on Safety and Efficacy of Cethromycin Presented at 47th Interscience Conference on Antimicrobial Agents and Chemotherapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... HOUSTON, TX , Feb. 27, 2015 /PRNewswire/ ... and Bloom Burton & Co. Ltd. ("Bloom Burton") today ... (the "Lock-Up") 2,353,130 common shares of the Company ("Common ... to the Lock-Up. Of the Common Shares released from ... upon release from the Lock-Up while the remainder will ...
(Date:2/27/2015)... Report Details   ... R&D progress, and predicted revenues ,Where is the market ... commercial prospects for this market and related technologies? Visiongain,s ... trends to 2025, discussing data, opportunities and prospects. ... regenerative medicine : cell-based therapies that aim to restore ...
(Date:2/27/2015)... 27, 2015 /CNW/ - Covalon Technologies Ltd. (the "Company" or ... announced financial results for its first quarter ended December ... ended December 31, 2014, revenue was $1,336,685. Operating expenses ... or $0.02 per share.  Covalon,s President ... very pleased with the significant progress we have made ...
Breaking Medicine Technology:ESSA Pharma and Bloom Burton announce additional release of shares from voluntary lock-up agreement 2ESSA Pharma and Bloom Burton announce additional release of shares from voluntary lock-up agreement 3ESSA Pharma and Bloom Burton announce additional release of shares from voluntary lock-up agreement 4Translational Regenerative Medicine: Market Prospects 2015-2025 2Translational Regenerative Medicine: Market Prospects 2015-2025 3Translational Regenerative Medicine: Market Prospects 2015-2025 4Translational Regenerative Medicine: Market Prospects 2015-2025 5Translational Regenerative Medicine: Market Prospects 2015-2025 6Translational Regenerative Medicine: Market Prospects 2015-2025 7Translational Regenerative Medicine: Market Prospects 2015-2025 8Covalon Announces First Quarter Financial Results 2Covalon Announces First Quarter Financial Results 3
... DIEGO, Dec. 22, 2011 ViroPharma Incorporated (NASDAQ: ... exclusive option to acquire Meritage Pharma, Inc., a private company ... suspension (OBS) as a treatment for eosinophilic esophagitis (EoE), a ... has paid an initial $7.5 million, and has agreed to ...
... Therapeutics, Inc. (Nasdaq: OREX ) today announced the ... consisted of one share of common stock and a warrant ... to the public of $1.45 per share of common stock ... stock, which together comprised the purchase price of $15.94 per ...
Cached Medicine Technology:ViroPharma Purchases Exclusive Option to Acquire Meritage Pharma 2ViroPharma Purchases Exclusive Option to Acquire Meritage Pharma 3ViroPharma Purchases Exclusive Option to Acquire Meritage Pharma 4ViroPharma Purchases Exclusive Option to Acquire Meritage Pharma 5ViroPharma Purchases Exclusive Option to Acquire Meritage Pharma 6ViroPharma Purchases Exclusive Option to Acquire Meritage Pharma 7Orexigen® Therapeutics Completes Public Offering of Common Stock and Warrants to Purchase Common Stock 2
(Date:2/27/2015)... Laguna Hills, CA (PRWEB) February 27, 2015 ... has been chosen as their Sage ERP Document Management ... ERP, Sage 300 ERP, Sage CRM and other complimentary ... ADSS Global have worked side-by-side for many years to ... their Sage ERP applications. , “We are thrilled ...
(Date:2/27/2015)... 27, 2015 The V Foundation for ... funding organizations, is excited to announce numerous promotions taking ... and many long-standing partnerships highlight The V Foundation’s significant ... expanding ways for all to get involved. Awarding ... cancer research, The V Foundation has funded more than ...
(Date:2/27/2015)... CA (PRWEB) February 27, 2015 On February ... “The Real Liquid Botox ,” that details the development ... that is working its way through FDA trials. For those ... cream is very attractive. Of course, if the drug ... prescription at a physician’s office. (see: goo.gl/PQvQwk) , “As the ...
(Date:2/27/2015)... The Dawn Greene Hospice, a 10-bed facility ... (MMW) on the Upper East Side, was officially dedicated and ... His Eminence Timothy Michael Cardinal Dolan. , Thomas J. Fahey, ... and a member of the ArchCare Board of Trustees, presided ... O.Carm, executive director of MMW, and Christina McInerney, president and ...
(Date:2/27/2015)... Calif. (PRWEB) February 27, 2015 The ... and research expertise have made it a beacon of ... and beyond, has been acknowledged by the national society ... the Huntington’s Disease Society of America — as ... , The acknowledgement recognizes the center’s service to over ...
Breaking Medicine News(10 mins):Health News:Altec Announces 2014 Sage ERP Document Management Partner of the Year Award Recipient 2Health News:The V Foundation Reinforces its Fight Against Cancer with New and Extended Partnerships 2Health News:The V Foundation Reinforces its Fight Against Cancer with New and Extended Partnerships 3Health News:Is Topical Botox the Next Big Thing? 2Health News:The Dawn Greene Hospice Is Officially Dedicated 2Health News:The Dawn Greene Hospice Is Officially Dedicated 3Health News:UC Davis Huntington's Disease Center Receives Level 1 Designation 2Health News:UC Davis Huntington's Disease Center Receives Level 1 Designation 3
... Diego, CA, August 2, 2011 Engaging in physical ... the odds of survival. In a study published in ... Preventive Medicine , researchers from the Israel Study Group ... (MI) survivors who lived in low socioeconomic status (SES) ...
... 29, 2011) − In a recent study published in ... University of Kentucky College of Nursing and Mark Pyles, ... at the College of Charleston, found smoke-free legislation does ... urban communities. This is true regardless of whether the ...
... -- Teens are much more likely to eat junk food ... with many fast food restaurants and other sources of unhealthy ... on junk food consumption by California teens living in neighborhoods ... food restaurants, convenience stores, dollar stores and liquor stores, with ...
... HealthDay Reporter , MONDAY, Aug. 1 (HealthDay News) -- ... after dinner. Play tag with your kids at the park. ... 150 minutes, or 2.5 hours, of moderate activity a week -- ... Those who did more -- about 300 minutes a week, ...
... Blocking a growth factor receptor cripples cancer growth in a ... online on August 1 in the Journal of Experimental ... cases of T cell acute lymphoblastic leukemia (T-ALL) carry genetic ... in aberrant activation of the cell. A study by Andrew ...
... 1, 2011) Two new studies published in the ... (JNM) provide insight into the potential of positron ... and to identify pharmaceuticals to slow the progress of ... the Alzheimer,s Association guidelines for detecting Alzheimer,s-related brain changes ...
Cached Medicine News:Health News:Heart attack survivors from poorer neighborhoods get less exercise 2Health News:Study finds smoke-free laws don't impact rural or urban economies 2Health News:With Junk Food Stores Nearby, Teens May Eat More of It 2Health News:Even a Little Exercise Helps the Heart, Study Finds 2Health News:Even a Little Exercise Helps the Heart, Study Finds 3Health News:New JNM research supports upcoming Alzheimer's disease guidelines 2
... CMC joint is the most common site for ... the CMC joint without restricting the wrist or ... persons who need to control or reduce subluxation ... perform work and leisure activities without pain. Also ...
... This is an excellent choice to treat ... MCP joint, basal joint arthritis, advanced carpal ... the thumb and wrist. Distal palmar ... flexion and full finger dexterity. Constructed ...
... CTi Wrist OTS is an off-the-shelf wrist orthotic designed ... of 3 pre-set ranges-of-motion (20°,35° and 50°). , ... sprains with TFCC tear-triangular fibrocartilage complex , ... nonunion , Partial tendon rupture , ...
... CTi Wrist Static is a solid, one-piece custom wrist ... stable, neutral position. , ,Indications: , Wrist ... fibrocartilage complex , Coles fracture - distal ... Partial tendon rupture , ORIF - Open ...
Medicine Products: